Xarelto (Rivaroxaban) is an FXa inhibitor indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for extended risk reduction. The blood thinner is manufactured by Bayer and is marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals. Xarelto was initially approved in 2011 and is one of the most recent blood thinners on the market. Xarelto medication is mostly prescribed to the patients who were gone through hip and knee replacement surgeries. The most serious potential side effects, complications and risks caused by Xarelto are severe internal bleeding, hemorrhaging and wrongful death, with no antidote available for doctors to control Xarelto bleeding events. Because of the high risk associated with the drug Xarelto have received two ‘black box’ warnings from the FDA.
As per a report released by the the Louisiana court, lawsuits against the blockbuster blood-thinning drug manufacturers, Xarelto have now reached 15000 across the country. As of December 15, 14,465 lawsuits are in process regarding Xarelto and according to the report all the Xarelto lawsuits will be consolidated for multidistrict litigation (MDL No. 2592) in Louisiana. About 1,000 cases are pending in a “mass-tort” at the state level in the Philadelphia Court of Common Pleas. The most of the lawsuits were filed against its manufacturers, Janssen Pharmaceuticals and Bayer AG alleging that these companies failed to warn patients and physicians of the increased risks of fatal internal bleeding when using Xarelto.
Xarelto Bellwether trials are set to begin in March 2017. The U.S. District Judge Eldon Fallon picked two cases for the first bellwether trial after inspecting more than 7000 Xarelto lawsuits. The four bellwether cases that have been selected scheduled to begin at Louisiana, Mississippi, and Texas; these cases could set the tone for future Xarelto lawsuits. Bellwether trials are used in mass tort actions when thousand of lawsuits have filed against one manufacturer and have similar allegations. The actual outcome from the judgment may be utilized for valuing groups of claims in settlements. In the MDL there will be thousands of cases challenging the safety of Bayer AG and Johnson & Johnson subsidiary Janssen’s blockbuster blood thinner Xarelto.
Bayer and Janssen Pharmaceuticals failed to adequately warn doctors as well as patients about the adverse effects cause by the life threatening drug Xarelto and the manufacturers were reckless in releasing the drug to market without a corresponding antidote, which can lead Xarelto to cause someone bleed to death. Thousands of lawsuit filed from all over the nation alleges that the manufacturers Bayer and Janssen knew or should have known of the risks associated with the drug. If you or your love ones are facing fatal complication due to real brad of Xarelto can take a legal action against the company. He/she can claim for reimbursement money against complication or loss within limited period of time. We have an experience attorneys group who evaluate your case free of cost unless we win the case for you. Contact Drugsclaim.com for free case review.